TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.270nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.330nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.470nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.640nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.700nMAssay Description:Inhibition of F protein D486N mutant in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effe...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.740nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.770nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.810nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 0.870nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 1.10nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 1.10nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 1.40nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 1.40nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 1.70nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 2.10nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 2.5nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 2.70nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 3.10nMAssay Description:Inhibition of F protein D486N mutant in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effe...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 4.60nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 7nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 8.10nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 11nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 13nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 17nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 17nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 17nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 17nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 17nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 21nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 23nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 24nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 24nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 24nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 25nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 26nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 32nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 40nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 47nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 50nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 53nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 54nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 55nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 58nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 59nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 63nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 64nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 68nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 69nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Taisho Pharmaceutical
Curated by ChEMBL
Taisho Pharmaceutical
Curated by ChEMBL
Affinity DataEC50: 70nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair